Home | Neuromuscular | Duchenne muscular dystrophy (DMD) | Publications | Publication: In vitro cytochrome P450 (CYP)- and transporter-mediated drug interaction potential of 6β-hydroxy-21-desacetyl deflazacort (6β-OH-21-desDFZ): A major human metabolite of deflazacort

Publication: In vitro cytochrome P450 (CYP)- and transporter-mediated drug interaction potential of 6β-hydroxy-21-desacetyl deflazacort (6β-OH-21-desDFZ): A major human metabolite of deflazacort

This research article, published in Pharmacology Research & Perspectives, evaluates CYP- and transporter-mediated drug interaction potentials of 6β-OH-21-desDFZ 

  • Learn more about the pharmacokinetic drug interaction potential of 6 β-OH-21-desDFZ, a major circulating but not biologically active metabolite of deflazacort (DFZ)
  • The in vitro CYP- and transporter-mediated drug interaction potentials of 6β-OH-21-desDFZ is systematically evaluated
  • A novel approach to preparing radioactively labeled 14C-6β-OH-21-desDFZ using microbial biotransformation for transporter substrate assay is also presented

Ma J, Beers B, Manohar R, et al. Pharmacol Res Perspect. 2021;9:e00748 

Once registered, you will be able to view the abstract and be provided the DOI and PubMed links for this publication. 

Deflazacort is a corticosteroid indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients 2 years of age and older. PTC Therapeutics is the Marketing Authorization Holder for deflazacort in the US only. Registration conditions differ internationally, and prescribing information may vary depending on local approval in each country. The US Prescribing Information for deflazacort is available here. Please refer to your local country guidance for more information.

Register now to unlock the content

Register now to access the content on this page

Already registered?
If not, register below

Registration
  • This Website is intended only for healthcare professionals (“Website“), is operated by PTC Therapeutics. (together with its affiliates “PTC”). In order to access the restricted content on this Website:

    *
    *
  • PTC will delete immediately the information provided if we cannot confirm you are a healthcare professional.
    Otherwise, in case of successful verification, PTC will retain the information provided for a period of two (2) years following your registration (i) only for the purposes of providing you access to this Website; and/or (ii) in case you signed up to receive PTC updates.

Providing your personal data and your consent is voluntary, and you have the right to withdraw your consent at any time, without giving any reasons. Please consult our Privacy Statement for more information on the processing of your personal data.
For any inquiry relating to the processing of your personal data or if you want to exercise your privacy related rights or withdraw your consent, you can contact PTC’s Privacy Office at: Dataprivacy@ptcbio.com.

You can unsubscribe from updates at any time when receiving an email from PTC.

US-DMD-0263 | April 2023
Sign in or register to access exclusive content on this site 
  REGISTER

Welcome to MEDhub

A website for healthcare professionals, provided by PTC Therapeutics

This educational website provides you with the latest scientific data and expert
insights on the diagnosis and management of a range of rare diseases across the neuromuscular system, central nervous system, and other areas

This content is protected. To view it please enter your email address below:

Register here to access the content on the site
US-CORP-0330 | July 2022

COMING SOON

The content you are trying to access is not currently available.

We will be updating the MEDhub site regularly to provide you with up-to-date, insightful expert-led content. To be notified when new additions become available, register now.